Olaptesed with immunotherapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called olaptesed combined with immunotherapy (pembrolizumab) and either one of two standard chemotherapy regimens for people with advanced pancreatic cancer that has stopped responding to first-line treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread to other parts of the body (metastatic).
- Your tumor is microsatellite-stable (MSS), which means it has a certain genetic makeup.
- You have already tried one standard chemotherapy (either gemcitabine/nab-paclitaxel or FOLFIRINOX) and it stopped working.
- You are generally well enough to care for yourself (ECOG score 0 or 1).
- Your blood tests show adequate liver, kidney, and bone marrow function.
- You have not had certain other cancer treatments within the last few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests whether combining pembrolizumab (an immunotherapy) with olaparib (a DNA-repair drug) can work better for people with metastatic (stage 4) pancreatic cancer. It targets tumors with certain lab marker results and aims to improve control of cancer growth.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.